Literature DB >> 3091058

Recombinant interferon-gamma and chemotherapy with isoniazid and rifampicin in experimental murine tuberculosis.

M Khor, D B Lowrie, A R Coates, D A Mitchison.   

Abstract

Viable bacterial counts in the lungs and spleens of mice infected intravenously with Mycobacterium tuberculosis, strain H37Rv were reduced by intravenous recombinant murine interferon-gamma (IFN-gamma) 1000-5000 u, but not by 200 u. Reduction in counts was greatest when IFN-gamma was given 1 day before infection and was not increased by additional doses in the preceding 2 days. The effect was complete in 1 day and was not increased by successive doses during the next week. Giving IFN-gamma in multilamellar liposomes further reduced the spleen viable counts, but this appeared due to the liposomes themselves and not to encapsulation of IFN-gamma within them. Only a minimal reduction in organ viable counts, not statistically significant, occurred when IFN-gamma was given 5 days after infection. Although IFN-gamma alone and isoniazid 25 mg/kg alone reduced the organ viable counts, combined treatment with IFN-gamma and isoniazid was no more bactericidal than isoniazid alone. Similarly, the bactericidal activity of rifampicin 25 mg/kg was not increased by simultaneous administration of IFN-gamma. There seems little likelihood that IFN-gamma would increase the efficacy of the early stages of the chemotherapy of tuberculosis.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3091058      PMCID: PMC2013056     

Source DB:  PubMed          Journal:  Br J Exp Pathol        ISSN: 0007-1021


  18 in total

1.  Analysis of the host-parasite equilibrium in chronic murine tuberculosis by total and viable bacillary counts.

Authors:  R J REES; P D HART
Journal:  Br J Exp Pathol       Date:  1961-02

2.  Protection of mice against fatal herpes simplex type 2 infection by liposomes containing muramyl tripeptide.

Authors:  W C Koff; S D Showalter; B Hampar; I J Fidler
Journal:  Science       Date:  1985-04-26       Impact factor: 47.728

3.  The effect of gamma-interferon during Mycobacterium bovis (BCG) infection in athymic and euthymic mice.

Authors:  D K Banerjee; A K Sharp; D B Lowrie
Journal:  Microb Pathog       Date:  1986-04       Impact factor: 3.738

4.  Preservation of mycobacteria: 100 percent viability of suspensions stored at -70 C.

Authors:  T H Kim; G P Kubica
Journal:  Appl Microbiol       Date:  1973-06

5.  In vitro activation of tumoricidal properties in rat alveolar macrophages by synthetic muramyl dipeptide encapsulated in liposomes.

Authors:  S Sone; I J Fidler
Journal:  Cell Immunol       Date:  1981-01-01       Impact factor: 4.868

6.  Involvement of macrophages in the eradication of established metastases following intravenous injection of liposomes containing macrophage activators.

Authors:  I J Fidler; Z Barnes; W E Fogler; R Kirsh; P Bugelski; G Poste
Journal:  Cancer Res       Date:  1982-02       Impact factor: 12.701

7.  Potentiation of antitumor effect of virus-induced interferon by mouse immune interferon preparations.

Authors:  W R Fleischmann; K M Kleyn; S Baron
Journal:  J Natl Cancer Inst       Date:  1980-11       Impact factor: 13.506

8.  Effect of treatment of mice with sera containing gamma interferon on the course of infection with Salmonella typhimurium strain LT-2.

Authors:  Z Izadkhah; A D Mandel; G Sonnenfeld
Journal:  J Interferon Res       Date:  1980

9.  Multiplication and survival of tubercle bacilli in the organs of mice.

Authors:  C H PIERCE; R J DUBOS; W B SCHAEFER
Journal:  J Exp Med       Date:  1953-02-01       Impact factor: 14.307

View more
  7 in total

1.  Treatment of tuberculosis using a combination of sustained-release rifampin-loaded microspheres and oral dosing with isoniazid.

Authors:  D C Quenelle; G A Winchester; J K Staas; E L Barrow; W W Barrow
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

2.  Efficacy of microencapsulated rifampin in Mycobacterium tuberculosis-infected mice.

Authors:  D C Quenelle; J K Staas; G A Winchester; E L Barrow; W W Barrow
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

Review 3.  Animal models in interferon research: some current trends.

Authors:  H Schellekens
Journal:  Experientia       Date:  1989-06-15

4.  Specific lysis of mycobacterial antigen-bearing macrophages by class II MHC-restricted polyclonal T cell lines in healthy donors or patients with tuberculosis.

Authors:  D S Kumararatne; A S Pithie; P Drysdale; J S Gaston; R Kiessling; P B Iles; C J Ellis; J Innes; R Wise
Journal:  Clin Exp Immunol       Date:  1990-06       Impact factor: 4.330

5.  Endogenous gamma interferon mediates resistance to Brucella abortus infection.

Authors:  Y Zhan; C Cheers
Journal:  Infect Immun       Date:  1993-11       Impact factor: 3.441

6.  Effects of gamma interferon and indomethacin in preventing Brucella abortus infections in mice.

Authors:  M G Stevens; G W Pugh; L B Tabatabai
Journal:  Infect Immun       Date:  1992-10       Impact factor: 3.441

7.  In vivo immune responses to Candida albicans modified by treatment with recombinant murine gamma interferon.

Authors:  R E Garner; U Kuruganti; C W Czarniecki; H H Chiu; J E Domer
Journal:  Infect Immun       Date:  1989-06       Impact factor: 3.441

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.